SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 144.14 |
| Enterprise Value ($M) | 80.00 |
| Book Value ($M) | 138.96 |
| Book Value / Share | 14.80 |
| Price / Book | 1.04 |
| NCAV ($M) | 57.98 |
| NCAV / Share | 6.17 |
| Price / NCAV | 2.49 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.47 |
| Return on Assets (ROA) | -0.44 |
| Return on Equity (ROE) | -0.58 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 9.41 |
| Current Ratio | 9.41 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 121.23 |
| Assets | 202.21 |
| Liabilities | 63.25 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 2.27 |
| Operating Income | -91.91 |
| Net Income | -83.58 |
| Earnings Per Share Basic And Diluted | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | -60.07 |
| Cash from Investing | -123.35 |
| Cash from Financing | 69.36 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | Citadel Advisors Llc | 3.90 | ||
| 13G | Driehaus Capital Management Llc | 5.28 | ||
| 13G | Alliancebernstein L.p. | 7.50 | ||
| 13G/A | Deep Track Capital, LP | 9.14 | 19.00 | |
| 13G/A | Cormorant Asset Management, LP | 2.86 | -49.77 | |
| 13G/A | Point72 Asset Management, L.P. | 7.80 | 32.99 | |
| 13G/A | Eventide Asset Management, Llc | 4.21 | -28.40 | |
| 13G/A | Fmr Llc | 6.23 | -20.30 | |
| 13G/A | Artal International S.C.A. | 4.50 | -1.32 | |
| 13D/A | New Enterprise Associates 17, L.P. | 11.80 | 1.66 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 6,812 | 29,302 | 23.25 | |
| 14,198 | 47,064 | 30.17 | |
| 8,979 | 60,373 | 14.87 | |
| 20,615 | 100,922 | 20.43 | |
| 17,970 | 74,829 | 24.01 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| JSPR – Jasper Therapeutics, Inc. | KALA – KALA BIO, Inc. |
| KPRX – Kiora Pharmaceuticals, Inc. | KTTA – Pasithea Therapeutics Corp. |
| KZR – Kezar Life Sciences, Inc. |
Financial data and stock pages provided by
Fintel.io